{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-046001","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.511064+00:00","generated_at":"2026-05-30T00:12:15.469590+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Elite Pharma Q2 FY2025 revenue $18.9M (+33% YoY); operating profit $3.5M (+84%)","bullets":["Consolidated revenue $18.9M for Q2 ended Sep 30, 2024, up $4.7M or 33% vs prior year.","Operating profit $3.5M, up $1.6M or 84% YoY, driven by higher Elite label product sales.","Conference call scheduled for Nov 15, 2024 at 11:30 AM EST to discuss results and business update.","Stockholders can submit financial questions by 7 PM EST on Nov 14 via dianne@elitepharma.com."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-046001","json":"https://secwatch.observer/filing/0001493152-24-046001.json","markdown":"https://secwatch.observer/filing/0001493152-24-046001.md","text":"https://secwatch.observer/filing/0001493152-24-046001.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315224046001/0001493152-24-046001-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315224046001/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:12:15.469590+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}